HC Wainwright Brokers Boost Earnings Estimates for Alumis

Alumis Inc. (NASDAQ:ALMS - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2025 earnings per share (EPS) estimates for shares of Alumis in a research report issued on Tuesday, April 22nd. HC Wainwright analyst M. Kapoor now expects that the company will earn ($1.03) per share for the quarter, up from their prior estimate of ($1.07). HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis' Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.74) EPS and FY2025 earnings at ($3.22) EPS.

Several other equities analysts have also issued reports on the stock. Oppenheimer began coverage on shares of Alumis in a report on Thursday, January 30th. They set an "outperform" rating and a $32.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Alumis in a research note on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $25.86.

Alumis Stock Down 0.7 %

Alumis stock traded down $0.03 during midday trading on Thursday, hitting $4.28. 181,460 shares of the company's stock were exchanged, compared to its average volume of 317,293. Alumis has a 12 month low of $3.18 and a 12 month high of $13.53. The firm has a 50-day moving average of $5.50 and a two-hundred day moving average of $7.66.

Insider Buying and Selling

In other news, Director Alan Colowick bought 16,104 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was purchased at an average price of $6.97 per share, with a total value of $112,244.88. Following the completion of the acquisition, the director now directly owns 16,104 shares of the company's stock, valued at $112,244.88. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martin Babler bought 15,650 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The stock was purchased at an average price of $6.44 per share, for a total transaction of $100,786.00. Following the transaction, the chief executive officer now owns 106,454 shares of the company's stock, valued at $685,563.76. The trade was a 17.23 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Trading of Alumis

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers boosted its holdings in Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock valued at $102,000 after purchasing an additional 2,949 shares during the last quarter. Tang Capital Management LLC grew its holdings in Alumis by 40.6% during the fourth quarter. Tang Capital Management LLC now owns 600,000 shares of the company's stock worth $4,716,000 after acquiring an additional 173,406 shares during the period. Foresite Capital Management V LLC raised its position in Alumis by 3.5% during the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company's stock valued at $45,426,000 after acquiring an additional 194,459 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Alumis by 1,257.0% in the fourth quarter. BNP Paribas Financial Markets now owns 34,835 shares of the company's stock valued at $274,000 after acquiring an additional 32,268 shares during the period. Finally, Ally Bridge Group NY LLC boosted its position in Alumis by 6.4% in the 4th quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company's stock worth $3,500,000 after purchasing an additional 26,843 shares in the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.